Mapmygenome®: Deriving valuable insights from DNA to empower people take charge of their well- being.

Have you ever thought of getting a view of your genetic behaviour through an astrological analogy or derive its taxonomy to get a broader perspective of your overall existence? Mapmygenome’s flagship offering “Genomepatri” studies the genetic sequence to trace the ancestral root and heritable diseases to help people revise their lifestyle choices.

Founded in 2012 by two passionate entrepreneurs Anu Acharya and Subash Lingareddy, Mapmygenome® offers advanced health solutions that are formulated by combining genetic health profiles and health history with genetic counseling. The objective of the company is to acquaint people about their health by analysing their genetic history and providing actionable steps that can assist them and the doctor’s move towards a healthier and better life.

Anu  Acharya’s entrepreneurial instincts persuaded her to start her entrepreneurial journey with Ocimum Bio solutions. This enterprising initiative was co-founded by IIT Kharagpur alumnus Subash Lingareddy. Their syndicate led to the establishment of a promising molecular diagnostics company- Mapmygenome®- one of the few companies in the country that work towards mitigating the gap between healthcare and personal health through cutting-edge technology and personal genomics. This information can help eliminate, prevent, treat and manage various types of hereditary diseases.

Backed by a powerful team of biotechnologists, statisticians, geneticists, bio informaticians, and medical counselors, Mapmygenome® brainstormed a wide spectrum of products and services, which also bestows healthcare providers with valuable information about their patients. This reduces the time and effort invested in analyzing and treating an ailment.

How do they work?

• Genomepatri Cardio: Genomics-based predictive risk assessment and management panel for cardiovascular diseases and diabetes.
• MyNutriGene: This helps in discovering the connection between genetics and diet. Through MyNutriGene individuals can conduct a detailed analysis of their eating habits which can have a huge impact on their fitness and help prevent diseases.
• MEDICAMAP: A cutting-edge pharmacogenomics test, which analyses an individual’s drug-response profile, based on genetic makeup.
• myfitgene: A program helps achieve cardio-respiratory fitness, muscle strength & endurance, body composition that aids in improving the strength and stamina of the body.
• Genomepatri Heritage: As the name suggests, this provision helps in unearthing the people’s ancestral origins. It decodes the DNA sequence and familiarizes people with their roots and their genetic behaviour.
• Genomepatri Immunity: A tool that enables users to identify gaps in immunity, including essential vitamins and minerals that contribute to immunity. This test also predicts risk for SARS-CoV and cytokine storm (adverse symptom of COVID-19).

Mapmygenome® has also invented other avant-garde offerings such as TB Test Kit, NGS Tests, Genetic Counseling, and Chromosomal Microarray Analysis (CMA). Taking a step further, the company has taken the initiative of conducting comprehensive screening of cancer using genomics. Each solution is composed of latest technology and sequencing platform that observes a simple and non-invasive sampling.

The company brought into play its creativity and innovation to mint Covisafe™- a collection kit for COVID diagnostic testing. CSIR-Centre for cellular and molecular biology validated and certified the kit to be as per ICMR protocols. The kit’s exclusive feature is the nasopharyngeal/oropharyngeal swab that is used to be placed in a stabilizing solution containing RNAShield™ (a proprietary US FDA approved reagent from US-based Zymo Research. The team designed Covisafe™ to ensure the safety of the healthcare providers and staff who collect the specimens. This kit is easy to handle and can be used in the labs. It is compatible with RNA extraction kits, does not require cold-chain transport and can be stored at temperatures less than 25 degrees for about 30 days. The kit does not allow the fluid sample to deteriorate even after passing through multiple freeze-thaw cycles.

When the first case of COVID-19 was diagnosed in India, their team worked round the clock to develop Genomepatri Immunity and an RT-PCR based COVID-19 test. They were among the first private labs in the state to offer NABL and ICMR approved tests to the public. Today, they have 2 labs (including one at Hyderabad International Airport) and many COVID-19 sample collection centers including drive-thru centers. They have expanded their portfolio to include antibody testing, rapid testing, and so forth.

Mapmygenome® has had an incredible journey of pioneering genomic technology and redefining the dimension of wellness and health by exploring individual genetic traits. The firm has created a niche for itself in the personal genomics industry, setting national and global footprints. In 2020, the company collaborated with Apollo Clinic to launch DNA-based health tests.

NASSCOM Center of Excellence IoT& AI vouchsafed Mapmygenome® with the opportunity of showcasing their successes in implementing digital technologies in healthcare, at its flagship healthcare initiative at the seventh edition of Lifesciences & Healthcare Innovation Forum (LHIF). This participation got them great interest from individuals as well as HCPs.

“Some of our recent achievements include the winning of ‘Technologies for Rural Healthcare’ category of 2019 edition, Achiever of the Pride of Telangana – 2018 awards in the Start-up category, Nasscom Emerge 50 2015 – League of 10 Profile, and many. We have bagged US$1.1 million in a pre-series A round of funding from Google India MD RajanAnandan and other angel investors in 2015 and concluded a deal that enabled us to secure around $20 million,” says Anu Acharya, Co-Founder & CEO, Mapmygenome®.

Mapmygenome® has set the bar high: it aims to expand its team, leadership, and counselling network. It endeavours to touch 100 million lives and save a million in the coming decade.

For any further information\query you can write to us at Co-innovate@nasscom.in